Compare · COYA vs NVO
COYA vs NVO
Side-by-side comparison of Coya Therapeutics Inc. (COYA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COYA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 1847.8x COYA ($103.4M).
- Over the past year, COYA is down 17.2% and NVO is down 44.1% - COYA leads by 27.0 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 3 for COYA).
- NVO has more recent analyst coverage (25 ratings vs 3 for COYA).
- Company
- Coya Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $4.63+4.51%
- $43.98+2.79%
- Market cap
- $103.4M
- $191.15B
- 1M return
- +7.67%
- -6.41%
- 1Y return
- -17.17%
- -44.13%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 3
- 8
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest COYA
- Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
- Roth Capital initiated coverage on Coya Therapeutics with a new price target
- Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
- SEC Form DEFA14A filed by Coya Therapeutics Inc.
- SEC Form DEF 14A filed by Coya Therapeutics Inc.
- Coya Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 424B5 filed by Coya Therapeutics Inc.
- SEC Form 10-Q filed by Coya Therapeutics Inc.
- Coya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care